Medical disclaimer. Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (obesity, obstructive sleep apnea with obesity). There is no FDA-approved "maintenance dose" — only a titration schedule to 15 mg. The low-dose maintenance protocols below are supported by emerging evidence (Horn 2025 SURMOUNT-MAINTAIN, readout May 2026) and real-world observational data (Rodriguez 2025 DOM), but are off-label relative to the approved titration. Microdosing and schedule-extension are community practices not yet tested in RCT. The peptide bridge compounds (tesamorelin, MOTS-c, NAD+) are off-label for the context described — tesamorelin is FDA-approved only for HIV lipodystrophy. Decisions about dosing, stopping, switching, or adding peptides belong with a clinician who knows your history.
Tirzepatide Maintenance Dose After Weight Loss
You hit goal weight on tirzepatide. Now the question is not whether to keep taking it — the regain data settled that — but at what dose, for how long, and with what surrounding protocol to preserve the body-composition advantage that made tirzepatide worth choosing over semaglutide in the first place.
The short answer is 5-10 mg weekly, indefinitely, with a lighter-touch option at 2.5 mg weekly or biweekly for maintainers who want to reduce drug load. The lower dose works because the GIP arm — the one carrying tirzepatide's body-composition advantage — holds most of its signal at 5 mg weekly.
| At a Glance | |
|---|---|
| Who this is for | Maintainers who reached goal weight on tirzepatide 10-15 mg and want to know the lower dose to hold it. |
| Standard maintenance dose | 5-10 mg weekly SubQ, indefinite. |
| Microdose / schedule-extension | 2.5 mg weekly, or 2.5-5 mg every 10-14 days (off-label, community practice). |
| Key trials | Horn 2025 Obesity (SURMOUNT-MAINTAIN design, readout May 2026), Aronne 2024 JAMA (SURMOUNT-4 — 14% regain on withdrawal, 89.5% of continuators hold ≥80% of loss), Sattar 2025 Lancet Diabetes Endocrinol (SURPASS-3 muscle MRI). |
| Lean-mass advantage | ~75:25 fat-to-lean loss on tirzepatide vs ~60:40 on semaglutide (SURMOUNT-1 DXA) — the reason to maintain rather than switch. |
| Peptide bridge | MOTS-c and NAD+ as HIGH priority during maintenance; tesamorelin LOWER priority (GIP is still doing visceral-fat work). Full profile. |
| Regulatory status | Tirzepatide FDA-approved. Low-dose maintenance is off-label relative to the labeled titration. Microdose and bridge compounds off-label. |
Why Tirzepatide Maintenance Works at a Lower Dose
Tirzepatide maintenance works at a lower dose because the GIP receptor — the arm that delivers its fat-selective, lean-sparing advantage — retains strong signaling at 2.5-5 mg weekly. Coskun 2018 (Molecular Metabolism) measured tirzepatide at 1.0x native GIP affinity and 0.2x native GLP-1 affinity. The GIP limb is the heavy lifter; it does not need MTD-level exposure to fire.
What actually gets reduced at maintenance dose is mostly GLP-1 appetite suppression. Gastric emptying speeds up modestly, between-meal hunger returns some, food noise drifts back up from zero to manageable. Maintainers compensate with food structure — protein front-loading at breakfast, fiber with every meal, pre-planned portions — rather than receptor pressure.
What is retained at maintenance dose is the more valuable half of the drug's effect. Fat cells burn more calories even at rest — a heat-producing calcium cycle inside adipocytes that semaglutide users do not activate at any dose (SERCA futile cycling, GIP-driven¹). Yu 2024 (Cell Metabolism) characterized the mechanism. This signal scales with receptor occupancy, and the GIP receptor saturates earlier than the GLP-1 receptor. You keep the body-composition advantage without carrying the MTD appetite suppression that most maintainers find uncomfortable long-term anyway.
Tirzepatide is a dual GLP-1/GIP agonist. For the triple-agonist version of this framework — where glucagon-receptor thermogenesis adds a third lever tirzepatide does not have — see our retatrutide post-stop protocol.
The practical implication: the question at maintenance is not "how much tirzepatide do I need to stay not-hungry?" It is "how much tirzepatide do I need to keep the GIP signal firing?" That number is lower than the appetite-focused titration schedule suggests, and it explains why 5 mg weekly is the dose Horn 2025 is formally testing rather than 10 or 15 mg.
The Standard Tirzepatide Maintenance Dose
The tirzepatide maintenance dose is typically 5-10 mg weekly SubQ — roughly half the 10-15 mg peak dose that drove the initial loss. Horn 2025 Obesity is the first RCT testing 5 mg vs MTD after a 60-week lead-in, readout May 2026. Aronne 2024 JAMA (SURMOUNT-4) already showed 89.5% of continuators held at least 80% of their loss over 52 weeks, vs 14% regain on placebo switch.
Step-down logic from peak dose:
| Phase | Weekly dose | Duration | Evidence anchor | Candidate |
|---|---|---|---|---|
| MTD continuation | 10, 12.5, or 15 mg | Indefinite | SURMOUNT-4 continuation arm | BMI still obese-range; appetite returns <72h without dose |
| First step-down | 7.5 mg | 8-12 weeks | Clinical practice extrapolation | Goal weight held 3+ months at MTD |
| Standard maintenance | 5 mg | Indefinite | Horn 2025 5 mg arm; SURMOUNT-4 logic | Goal weight stable; tolerating well |
| Low-dose maintenance | 2.5 mg | Indefinite | Rodriguez 2025 DOM (RWE) | Strong lifestyle base; want lower drug load |
| Schedule-extended | 2.5-5 mg every 10-14 days | Indefinite | Community practice, no RCT | See H2 below |
The titration-down rhythm most maintainers follow runs 15 → 10 → 7.5 → 5 mg, holding each step 8-12 weeks to see whether weight drifts before reducing again. Step-down is not mandatory — the SURMOUNT-4 continuation arm stayed at MTD and held losses fine. But many maintainers dislike the appetite flatness of MTD once they are no longer actively losing, and dropping to 5 mg usually restores a normal-feeling hunger signal without triggering regain.
When NOT to reduce: BMI still in the obese range (reduction is premature), hunger returns within 72 hours of injection (GLP-1 arm is doing more work than the GIP arm in your body-comp profile), weight creeps more than 2 lb per month at the step-down dose, or training strength trends down despite protein adherence. In any of those cases, hold the higher dose and revisit in 8 weeks.
From a reconstitution standpoint, 5 mg doses from a 10 mg vial and 2.5 mg from a 5 mg vial are the clean splits — see the reconstitution guide for the sub-milligram draw mechanics and the GLP-1 dosing calculator for volume conversions.
If you experience persistent GI symptoms, heart-rate drops, or gallbladder-related pain at any dose, see your doctor — those are not expected on maintenance.
Microdosing and Schedule-Extension Protocols
Off-label. The 2.5 mg weekly and schedule-extension protocols below are community practice, not tested in RCT. Real-world observational data (Rodriguez 2025 Diabetes Obesity and Metabolism — ~1,500 patients maintaining at 2.5-5 mg) supports feasibility. No maintenance-dose RCT below 5 mg exists. Frame accordingly.
Microdosing tirzepatide for maintenance means holding at 2.5 mg weekly, or extending the schedule to 2.5-5 mg every 10-14 days — lower than any FDA-approved dose and not tested in a controlled trial. Rodriguez 2025 DOM real-world observational data supports feasibility in patients already stable at goal weight with strong lifestyle anchors. It is off-label.
Three schedules dominate community practice:
| Schedule | Equivalent weekly | Reconstitution note | Candidate |
|---|---|---|---|
| 2.5 mg weekly | 2.5 mg | 0.25 mL from a 5 mg/0.5 mL vial | Goal weight held 6+ months at 5 mg; wants lower drug load |
| 2.5 mg every 10 days | ~1.75 mg | Same draw, extended interval | Mild hunger drift on 2.5 mg weekly; wants lighter touch |
| 5 mg every 14 days | 2.5 mg | 0.5 mL from a 5 mg vial | Prefers fewer injection days; tolerates longer GLP-1 valleys |
Tirzepatide's half-life is ~5 days. On a biweekly schedule, blood levels drop roughly 85% between doses — the valley is real, and it is where maintenance failure shows up first. Hunger climbs in the back half of the interval, weight drifts, and many maintainers walk the schedule back to weekly.
A maintainer on r/TirzMaintenance (late 2025) described the common step-down arc: "Started at 10, dropped to 5 after a year at goal, tried 2.5 weekly for four months and it held. Tried biweekly and hunger came back hard by day 10. Went back to 2.5 weekly. It's my floor." Community post, approximate late 2025. Anecdotal — included for texture, not evidence.
For post-compounded-ban reconstitution math on sub-2.5 mg draws, the tirzepatide dosing calculator and the reconstitution guide handle the arithmetic. The supply landscape has shifted since the FDA ended the compounding exemption, and most maintainers on low-dose protocols are now splitting branded 5 mg or 10 mg vials rather than sourcing compounded.
Lean Mass Preservation During Maintenance
Tirzepatide preserves lean mass better than semaglutide — roughly 75:25 fat-to-lean loss vs sema's ~60:40, per SURMOUNT-1 DXA. Sattar 2025 (Lancet Diabetes Endocrinol), the SURPASS-3 MRI, showed tirzepatide-treated T2D patients improved thigh muscle-volume Z-score and reduced myosteatosis vs weight-matched UK Biobank controls. The GIP-driven futile-cycling mechanism delivers this at maintenance dose, not just peak.
This is the single best argument for staying on tirzepatide rather than switching to semaglutide when cost or supply pressure tempts the switch. Forty percent of every pound a semaglutide maintainer loses (and — more relevantly — of every pound they might regain) is lean tissue; for tirzepatide the equivalent number is 25%. Over multi-year maintenance, the body-composition trajectories diverge meaningfully, even when scale weight looks identical.
Sattar 2025 is the moat here. It is the only published MRI-grade muscle data on tirzepatide at scale, and it points the opposite direction most maintainers expect: tirzepatide-treated patients were adding muscle quality (less intramuscular fat) and preserving volume beyond what weight-matched non-pharmacological controls managed. The likely mechanism is GIP's combination of fat-selective loss bias plus insulin-sensitizing effects on muscle nutrient partitioning — muscle gets a larger share of dietary amino acids when GIP signaling is active.
Maintenance dosing preserves this trajectory. The GIP futile-calcium-cycling signal that biases loss toward fat does not require MTD — Yu 2024 mechanism data shows receptor saturation at lower exposure than the appetite-suppression curve. What maintenance does require is the training and protein layer:
- Protein: ≥1.6 g/kg body weight daily, distributed across 3-4 meals with 30-50 g each. Leucine threshold matters per meal.
- Training: 3-5 resistance sessions per week with compound lifts (squat, deadlift, press, row, pull-up). Progressive overload. Cardio supports, does not replace.
- Leading indicator: big-three strength tracked weekly. Strength trending up = lean mass holding. Strength flat or down for 4+ weeks = audit protein intake and training volume before touching the dose.
Deeper coverage in GLP-1 Lean Mass.
The Peptide Bridge for Tirzepatide Maintenance
Off-label / research-grade. The peptide bridge compounds below are not FDA-approved for maintenance support after GLP-1 weight loss. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy and is used off-label here. MOTS-c and NAD+ injectables are research-grade. No RCT has tested this bridge combination.
The bridge for tirzepatide maintenance is meaningfully lighter than the bridge after stopping retatrutide, and the reason is mechanistic: the GIP arm is still firing during maintenance. Visceral fat signaling, mitochondrial fuel partitioning, and some thermogenic lift are all still coming from the drug. The bridge fills gaps, rather than replacing the whole metabolic engine.
| Compound | Dose | Maintenance priority | Post-stop priority | Why |
|---|---|---|---|---|
| MOTS-c | 5-10 mg twice weekly SubQ | HIGH | HIGH | Mitochondrial AMPK activation complements GIP-driven fuel oxidation (Lee 2015 Cell Metabolism). Stacks cleanly at any tirzepatide dose. Profile. |
| NAD+ | 100-200 mg 5x/week SubQ or IM | HIGH | HIGH | Cofactor capacity for beta-oxidation — more valuable at lower tirz doses when endogenous metabolic rate is less boosted (Yoshino 2021). Profile. |
| Tesamorelin | 1-2 mg nightly SubQ | LOW (conditional) | MODERATE | FDA-approved for HIV lipodystrophy; off-label here. Lower priority during maintenance because GIP is still driving visceral-fat signaling. Add only if waist/DXA VAT is rebounding or liver enzymes drift (Stanley 2019 Lancet HIV). Profile. |
| L-carnitine (optional) | 500-1000 mg IM pre-training | LOW | LOW | CPT-1 support for fasted training. Noise-level intervention but cheap. |
Why tesamorelin is lower priority on tirz than reta. This is the part of the bridge logic most articles miss. Tesamorelin's main job post-GLP-1 is replacing visceral-fat-oxidation signaling that the drug was providing. On retatrutide, the glucagon arm was doing heavy visceral and hepatic fat work — stopping it creates a real gap. On tirzepatide maintenance, the tissue-level fat-burning signal from GIP (Yu 2024¹) is still active at 5 mg weekly; visceral fat signaling is still firing. Adding tesamorelin on top is redundant unless the metrics say otherwise. Save it for post-stop, or for maintainers whose VAT is visibly rebounding despite dose adherence.
Why MOTS-c and NAD+ stay high priority. Both operate upstream of the receptor chain. MOTS-c activates AMPK at the mitochondrial level — complementary to, not overlapping with, anything the GLP-1 or GIP arms are doing. NAD+ is the electron-transport cofactor that fat oxidation depends on at any dose of anything. Neither gets redundant just because tirzepatide is still on board.
Sequencing. Start the bridge when you step down from MTD to maintenance dose, not after. The point is replacement signaling already in place before the GLP-1 appetite pressure drops. See the peptide stacking guide for timing and compatibility across compounds.
What to Track During Maintenance
Maintenance is a monitoring problem, not a titration problem. The metrics that matter:
| Metric | Frequency | What it tells you | Action threshold |
|---|---|---|---|
| Weight | Weekly, same conditions (morning, fasted, post-void) | Overall trajectory | >2 lb sustained drift up over 3 weeks → evaluate |
| Waist | Biweekly | Visceral fat signal; best single proxy for metabolic health | >1 inch drift up over 8 weeks → check tesamorelin add |
| Hunger score (1-10) | Daily, morning | Early warning that dose is too low | Score >7 for 7+ days → evaluate dose |
Why the hunger score matters more than the scale: an r/TirzMaintenance maintainer captured the pattern — "I only increased because I felt the hunger and cravings coming back a little. That was my signal — before the weight moved." (r/TirzMaintenance community post, approximate 2025. Anecdotal — included for texture, not evidence.) Hunger drift precedes scale drift by weeks. A daily 1–10 rating gives you the earliest warning that the dose is sliding out of its effective window.
| Big-three strength | Weekly lifts tracked | Leading indicator of lean-mass preservation | Flat or declining 4+ weeks → protein/training audit |
|---|---|---|---|
| Resting heart rate | Biweekly | Adrenergic/autonomic balance | >10 bpm drop or climb → clinician |
| Energy / fatigue | Daily subjective | Tirzepatide-specific pattern — see GLP-1 fatigue | Persistent fatigue → audit NAD+ and MOTS-c timing |
The rule that keeps maintainers out of trouble: react to trends, not single readings. A 2 lb week-over-week gain on one weigh-in is noise. A 2 lb gain that holds three weeks is signal.
When You Are Ready to Stop Tirzepatide
Stopping tirzepatide after maintenance is not dangerous — there is no withdrawal syndrome. But without a protocol, Aronne 2024 SURMOUNT-4 (JAMA) projects ~14% body-weight regain over 52 weeks. The three forces driving regain are appetite return as tirzepatide washes out, lean-mass-driven BMR contraction, and hormonal set-point rebound. The fix is a 12-16 week taper with training, protein, and peptide bridge already in place.
Tirzepatide post-stop is a three-force problem: appetite return, BMR contraction from lost lean mass, and hormonal set-point rebound. Retatrutide post-stop is a four-force problem because it adds glucagon-axis thermogenic withdrawal — detailed separately in our retatrutide post-stop protocol. If you are on tirzepatide, you do not inherit the fourth force. The taper architecture is correspondingly lighter.
The GIP arm's effect on ghrelin is weak and insulin-mediated (Lugari 2005¹) — it does not add a mechanistically independent suppression path the way retatrutide's glucagon arm does, so tirzepatide discontinuation does not carry the compound two-arm ghrelin release reta users face.
A representative taper from maintenance dose to zero:
| Phase | Duration | Dose | Purpose |
|---|---|---|---|
| Pre-taper bridge install | 4 weeks | 5 mg weekly (maintenance continued) | MOTS-c + NAD+ active before any dose drop |
| Step 1 | 4-6 weeks | 2.5 mg weekly | First appetite test; training and protein locked |
| Step 2 | 4-6 weeks | 2.5 mg every 2 weeks | Second valley; watch hunger-score drift |
| Off | Ongoing | 0 mg | Maintenance by lifestyle + bridge |
Tirzepatide has a ~5-day half-life. After the final dose, appetite-suppression effects fade over roughly 30 days. Aronne 2024 SURMOUNT-4 documented the regain curve: on placebo switch from maintenance, patients regained ~14% of body weight over 52 weeks, vs continuators who held 89.5% of their loss to the ≥80%-held threshold. The three forces accumulate on different timelines — appetite first, set-point second, lean-mass BMR permanent — and the bridge buys time to adapt.
An r/Zepbound post-stop thread (early 2026) captured the appetite-return timing: "Week 3 I noticed food started sounding good again. Week 5 it was louder. By week 7 I was back to counting and that was the new normal." Community post, approximate early 2026. Anecdotal — consistent with the ~30-day washout curve.
If you experience sharp hunger return, rapid weight regain (>5 lb in 4 weeks), or metabolic marker drift during taper, see your doctor — restart at maintenance dose is a legitimate tool, not a failure.
Decision Framework: Stay, Step Down, Switch, or Stop
This is a decision structure, not a prescription. The right option depends on cost tolerance, body-comp priority, and how much lifestyle support is already locked in.
| Option | Best for | Dose | Bridge layer | Monitoring signal |
|---|---|---|---|---|
| Stay at effective dose | Tolerating well; cost not an issue; still losing or recently at goal | 5-10 mg weekly, indefinite | MOTS-c + NAD+ standard | Waist, strength, energy |
| Step down to low-dose / microdose | Good maintainer; wants lower drug load; strong lifestyle base | 2.5 mg weekly, or 2.5-5 mg every 10-14 days | MOTS-c + NAD+ standard | Hunger score, waist drift |
| Switch to semaglutide maintenance | Cost-driven; supply disruption; Rybelsus oral preferred | 0.25-1.7 mg weekly SubQ | Tesamorelin priority rises (no GIP arm) | Body-comp ratio drift (60:40 vs 75:25) |
| Full stop with bridge + training | Goal held 6+ months at maintenance; strong training base | 12-16 week taper per above | Bridge installed pre-taper | All H2-6 metrics |
The switching-to-semaglutide option deserves its own note. Semaglutide is cheaper, more available in post-compounding-ban supply, and has a longer half-life (~7 days vs tirzepatide's ~5). What you lose is the GIP arm — which means the 75:25 fat-to-lean loss ratio drops toward 60:40, tesamorelin moves from LOW to HIGH priority in the bridge, and the compositional advantage that made tirzepatide worth choosing erodes. For maintainers who prioritize scale weight over body composition, the switch is reasonable. For those who care about the muscle-quality trajectory, staying on tirzepatide at 2.5 mg weekly is usually the better call.
How Tirzepatide Maintenance Compares to Semaglutide and Retatrutide
| Compound | Peak dose | Typical maintenance | Withdrawal regain | Lean advantage | Key maintenance trial |
|---|---|---|---|---|---|
| Semaglutide | 2.4 mg weekly | 0.25-1.7 mg weekly (2.4 mg if needed) | ~15 pp swing on withdrawal (Rubino 2021 STEP-4 JAMA) | ~60:40 fat:lean | STEP-4 (published) |
| Tirzepatide | 10-15 mg weekly | 5-10 mg weekly standard; 2.5 mg weekly microdose | *~14% over 52 weeks (Aronne 2024 SURMOUNT-4 JAMA)* | ~75:25 fat:lean (SURMOUNT-1 DXA) | Horn 2025 SURMOUNT-MAINTAIN (readout May 2026) |
| Retatrutide | 8-12 mg weekly | 2-4 mg weekly (extrapolated) | No withdrawal RCT — extrapolated steeper than tirz | ~75:25 projected | TRIUMPH-4 (no dedicated maintenance trial yet)¹ |
¹ Retatrutide maintenance and withdrawal curves are currently extrapolated — no dedicated withdrawal RCT exists. See our retatrutide post-stop protocol for the four-force framework, glucagon-axis physiology, and heavier-bridge rationale.
The row that matters most for anyone choosing between tirzepatide and semaglutide maintenance is the lean-mass column. Horn 2025 will eventually settle the exact 5 mg vs 10 mg vs MTD maintenance question for tirzepatide. It will not change the compositional advantage over semaglutide — that is a mechanism-level difference (GIP vs no GIP), not a dose-level one.
Honest Gaps in the Evidence
- Horn 2025 SURMOUNT-MAINTAIN reads out May 2026. Until then, the 5 mg maintenance dose is evidence-adjacent, not evidence-backed by RCT. The design is the first rigorous test of whether sub-MTD maintenance holds — 3:3:2 randomization of MTD vs 5 mg vs placebo after a 60-week open-label lead-in, 52-week maintenance phase, week-112 primary endpoint among patients with weight plateau weeks 48-60.
- No RCT has tested schedule-extension protocols. Biweekly and every-10-day dosing are community self-report and Rodriguez 2025 DOM observational — not controlled. The PK valley is real; whether the efficacy valley is real is unanswered.
- Switching tirzepatide → semaglutide has no direct trial. Extrapolated from class effect plus SURMOUNT-4 and STEP-4 separately. The body-comp drift prediction is mechanism-driven.
- Tirzepatide lean-mass data in non-diabetic obesity at maintenance doses is extrapolation from SURMOUNT-1 DXA (peak dose) and Sattar 2025 SURPASS-3 MRI (T2D). The exact maintenance-dose body-comp trajectory awaits SURMOUNT-MAINTAIN.
- The peptide bridge has zero RCT support as a protocol. Each component has individual trial evidence (Stanley 2019 tesamorelin for visceral fat; Lee 2015 MOTS-c; Yoshino 2021 NAD+). The integrated use in the tirzepatide maintenance context has not been tested.
SURMOUNT-MAINTAIN reads out May 2026; until then the 5 mg arm is evidence-adjacent, not RCT-confirmed.
FAQ
What is the maintenance dose of tirzepatide?
Typically 5-10 mg weekly SubQ — roughly half the 10-15 mg peak dose. A lower track runs 2.5 mg weekly or 2.5-5 mg every 10-14 days. Horn 2025 SURMOUNT-MAINTAIN is the first RCT formally testing 5 mg.
Can you microdose tirzepatide for maintenance?
Yes — 2.5 mg weekly or 2.5-5 mg every 10-14 days is documented community practice with real-world observational support (Rodriguez 2025 DOM). It is off-label and not RCT-tested. Best for maintainers already stable at goal with strong lifestyle support.
Can I take tirzepatide every other week for maintenance?
Possible but the PK valley is real — tirzepatide has a ~5-day half-life, so biweekly drops blood levels ~85% between doses. Many maintainers find hunger climbs back days 8-14. If you try it, track hunger score daily and walk back to weekly if drift appears.
Can I take tirzepatide once a month?
Not recommended. At monthly intervals the drug is effectively absent for the last 2 weeks of the cycle. No evidence supports efficacy at that spacing.
Can I switch from tirzepatide to semaglutide for maintenance?
Yes — typical switch lands at semaglutide 0.25-1.0 mg weekly SubQ. Accept the body-comp tradeoff (sema's 60:40 fat:lean ratio vs tirz's 75:25). Tesamorelin priority rises in the bridge because semaglutide has no GIP arm doing lean-mass work.
What happens when you stop taking tirzepatide?
<!-- AIO-TARGET: What happens when you stop taking tirzepatide -->
No withdrawal syndrome. Appetite returns over weeks 3-6 as the drug washes out, lean-mass-driven BMR contraction is permanent unless rebuilt, and hormonal set-point rebound (Sumithran 2011) persists ~12 months. Aronne 2024 SURMOUNT-4 showed ~14% body-weight regain over 52 weeks without a maintenance protocol.
Can you stop tirzepatide cold turkey?
Yes, safely — but cold turkey sets up regain. Tapering from maintenance dose over 12-16 weeks, with resistance training and the peptide bridge already installed, is the protocol that holds losses.
Do you gain weight back after stopping tirzepatide?
Without a protocol, yes — ~14% over 52 weeks on average (SURMOUNT-4). With a protocol (taper, ≥1.6 g/kg protein, resistance training, bridge), weight typically holds. The mechanism, not willpower, determines the outcome.
How do you keep weight off after stopping tirzepatide?
Three layers: (1) taper rather than cold-turkey — 12-16 weeks from maintenance to zero, (2) ≥1.6 g/kg protein and 3-5 resistance sessions per week from before the final dose, (3) peptide bridge (MOTS-c + NAD+) installed pre-taper.
Is there a lower compounded tirzepatide maintenance dose?
The post-compounding-ban landscape has shifted most low-dose maintainers onto branded 5 mg or 10 mg vials split into 2.5 mg doses. See the reconstitution guide for sub-milligram draw mechanics.
Related Topics
- Tirzepatide — full profile, mechanism, dosing
- Post-GLP-1 Protocol: Retatrutide — sister article, four-force framework for triple-agonist
- GLP-1 Lean Mass, GLP-1 Fatigue
- Tesamorelin, MOTS-c, NAD+ Guide
- Peptide Stacking Guide
- GLP-1 Dosing Calculator, Reconstitution Guide
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.